APA (7th ed.) Citation

AA, O., K, T., M, O., SC, M., T, M., & K, S. (2022). Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup. Advances in therapy, 39(6), 2984. https://doi.org/10.1007/s12325-022-02162-w

Chicago Style (17th ed.) Citation

AA, Okada, Takahashi K, Ohji M, Moon SC, Machewitz T, and Sasaki K. "Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup." Advances in Therapy 39, no. 6 (2022): 2984. https://doi.org/10.1007/s12325-022-02162-w.

MLA (9th ed.) Citation

AA, Okada, et al. "Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup." Advances in Therapy, vol. 39, no. 6, 2022, p. 2984, https://doi.org/10.1007/s12325-022-02162-w.